-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent studies have shown that an inhaled, non-hormonal anti-inflammatory drug, sodium ibuprofen (NaIHS) dissolved in hypertonic sodium salts, can relieve hypoxia symptoms in patients with moderate to severe COVID-19 pneumonia
.
However, the relevant molecular mechanism is still unclear
.
The authors hypothesized that the effect of NaIHS is related to indirect inhibition of high production of nitric oxide (NO) in the body
.
When a patient with COVID-19 presents with symptoms of vasoplegia, we call it COVID-19 L type
.
70-80% of COVID-19 patients are COVID-19 L type
.
Of the 383 COVID-19 patients enrolled, 15% had been treated with mechanical ventilation
.
Regardless of race, and whether it is a mechanical ventilation group or a non-mechanical ventilation group of COVID-19 patients, after correcting the respiratory rate, the patient's hypoxemia will be effectively reversed, the hospital stay will be shortened, and the mortality rate will be reduced.
decreased, which was associated with a reduction in the half-life of gaseous NO (usually 1-5 seconds) by the treatment
.
When NO harms the human body, its concentration is at the micromolar level and is concentration-dependent
.
On January 23, 2022, the journal Clinical and Translational Discovery published online the latest achievement "Potential reversal of pulmonary vasoplegia by inhaled ibuprofenate in COVID-19 pneumonia" from the team of Professor Christian Carlos Zurita-Lizza in Argentina[6] (
